Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study
Authors
Kim, W. S.Oki, Y.
Kim, S. J.
Yoon, S. E.
Ardeshna, K. M.
Lin, Y.
Ruan, J.
Porcu, P.
Brammer, J. E.
Jacobsen, E. D.
Yoon, D. H.
Suh, C.
Suarez, F.
Radford, John A
Budde, L. E.
Kim, J. S.
Bachy, E.
Lee, H. J.
Bollard, C. M.
Jaccard, A.
Kang, H. J.
Inman, S.
Murray, M.
Combs, K. E.
Lee, D. Y.
Advani, R.
Gunter, K. C.
Rooney, C. M
Heslop, H. E.
Affiliation
Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, South Korea.Issue Date
2021
Metadata
Show full item recordAbstract
We conducted a phase II clinical trial to develop an autologous EBV-specific T cell product (baltaleucel T) for advanced, relapsed ENKTL. Among 47 patients who provided whole blood starting material for manufacturing the product, 15 patients received a median of 4 doses of baltaleucel T. Thirty-two (68%) patients did not receive baltaleucel-T due to manufacturing failure, rapid disease progression, and death. Of the 15 patients, 10 patients had measurable disease at baseline (salvage cohort), and 5 patients had no disease at baseline assessment (adjuvant cohort). In the 15 patients, the median follow-up duration was 10.2 months (range 2.0-23.5 months), median progression-free survival (PFS) was 3.9 months, and the median overall survival (OS) was not reached. Patients in the salvage cohort achieved a 30% complete response (CR) and a 50% overall response rate (ORR). In the adjuvant cohort, disease progression was reported in three patients and two patients did not relapse during study follow-up. When we compared survival outcomes of seven responders and eight non-responders, the PFS (P = 0.001) and OS (P = 0.014) of responders proved statistically superior to that of non-responders. Baltaleucel-T was well tolerated. We have performed a phase II clinical trial of autologous EBV-specific T cell treatment (baltaleucel-T) in R/R ENKTL. Autologous EBV-specific T cells were well tolerated and demonstrated single-agent activity in R/R ENTKL.Citation
Kim WS, Oki Y, Kim SJ, Yoon SE, Ardeshna KM, Lin Y, et al. Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. Ann Hematol. 2021 Jul 24.Journal
Annals of HematologyDOI
10.1007/s00277-021-04558-0PubMed ID
34304287Additional Links
https://dx.doi.org/10.1007/s00277-021-04558-0Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1007/s00277-021-04558-0